Racial differences in long-term adjuvant endocrine therapy adherence and mortality among Medicaid-insured breast cancer patients in Texas: Findings from TCR-Medicaid linked data

Table 4 Cox regression result of the effect of adherence on survival

	One-year adherence to AET		Three-year adherence to AET		Five-year adherence to AET
Model	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value
Adherence	0.75 (0.61-0.92)	<0.01	0.60 (0.44-0.83)	<0.01	0.59 (0.34-1.01)	0.05
Adherence + Race	0.79 (0.64-0.97)	<0.05	0.64 (0.46-0.89)	<0.01	0.63 (0.36-1.07)	0.09
Adherence + Race+ Age	0.80 (0.65-0.98)	<0.05	0.65 (0.47-0.90)	<0.01	0.64 (0.37-1.10)	0.10
Adherence + Race+ Age+ Stage+ Comorbidity	0.84 (0.68-1.04)	0.12	0.65 (0.46-0.90)	<0.01	0.58 (0.33-1.03)	0.06
Adherence + Race+ Age+ Stage+ Comorbidity+ SES^a	0.85 (0.68-1.05)	0.13	0.62 (0.44-0.87)	<0.01	0.55 (0.31-0.99)	<0.05
Full model^b	0.87 (0.70-1.07)	0.19	0.66 (0.47-0.92)	<0.05	0.54 (0.30-0.99)	<0.05

^aSES variables include Poverty level, DPC physicians per 100 population, TX-Mexico border, Region
^bFull model includes model 5 plus chemotherapy, radiation therapy, surgery treatment or not and patient year of diagnosis

ISSN: 1471-2407